Uruguay marijuana draws pharmaceuticals' interest: report

Foreign pharmaceutical companies have expressed interest in buying marijuana for medical uses from Uruguay, which last month became the world's first country to legalize the cultivation and sale of the drug, local media reported Monday.

The newspaper El Observador said the National Drug Board has been in contact with pharmaceutical laboratories from Israel and Chile, while Canadian businesses have contacted Uruguayan politicians and organizations to present proposals for buying cannabis.

"It is true they have consulted us to set up in Uruguay, which is a great challenge," presidential aide Diego Canepa told the newspaper.

Uruguay became the first country to legalize the cultivation, distribution and sale of marijuana December 24 when President Jose Mujica signed a law creating a government-regulated marketplace for the .

His government is currently drawing up specific rules and regulations that will apply.

The National Drug Board says it expects cannabis to go to market beginning in September.

"While it was not an objective of the law, Uruguay is becoming a biotechnology pole. It's a highly competitive area, but one that is rapidly developing," Canepa said.

"For some time, medicinal was only thought of as an analgesic, but now they are studying whether some derivatives can be used in medications," he said.

add to favorites email to friend print save as pdf

Related Stories

New York may allow medical marijuana use: report

Jan 05, 2014

New York is planning to loosen its marijuana laws to allow limited use of the drug by people suffering serious illness, the New York Times reported Saturday, citing state officials.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments